Perfusion imaging heterogeneity during NO inhalation distinguishes pulmonary arterial hypertension (PAH) from healthy subjects and has potential as an imaging biomarker

BACKGROUND: Without aggressive treatment, pulmonary arterial hypertension (PAH) has a 5-year mortality of approximately 40%. A patient’s response to vasodilators at diagnosis impacts the therapeutic options and prognosis. We hypothesized that analyzing perfusion images acquired before and during vas...

Descripción completa

Detalles Bibliográficos
Autores principales: Winkler, Tilo, Kohli, Puja, Kelly, Vanessa J., Kehl, Ekaterina G., Witkin, Alison S., Rodriguez-Lopez, Josanna M., Hibbert, Kathryn A., Kone, Mamary T., Systrom, David M., Waxman, Aaron B., Venegas, Jose G., Channick, Richard N., Harris, R. Scott
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714016/
https://www.ncbi.nlm.nih.gov/pubmed/36457013
http://dx.doi.org/10.1186/s12931-022-02239-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714016/
https://www.ncbi.nlm.nih.gov/pubmed/36457013
http://dx.doi.org/10.1186/s12931-022-02239-8

Ejemplares similares